Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1989-6-7
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0369-8114
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
37
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
159-60
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:2652071-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2652071-Doxorubicin,
pubmed-meshheading:2652071-Epirubicin,
pubmed-meshheading:2652071-Humans,
pubmed-meshheading:2652071-Intercalating Agents,
pubmed-meshheading:2652071-Mitoxantrone,
pubmed-meshheading:2652071-Neoplasms
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
[Advances in intercalating drugs].
|
| pubmed:affiliation |
Service de Médecine Oncologique, Institut Curie, Paris, France.
|
| pubmed:publicationType |
Journal Article
|